Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Price Target at $106.85

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $104.5385.

SLNO has been the topic of a number of analyst reports. TD Cowen dropped their price objective on Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a research note on Monday, January 12th. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a report on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Finally, Oppenheimer cut their price target on shares of Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating for the company in a research note on Wednesday.

Soleno Therapeutics Trading Down 1.2%

Soleno Therapeutics stock opened at $33.22 on Monday. The company has a market cap of $1.71 billion, a price-to-earnings ratio of 144.44 and a beta of -3.16. The firm has a 50-day moving average of $39.58 and a 200-day moving average of $49.97. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. Soleno Therapeutics has a one year low of $32.15 and a one year high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. On average, equities analysts expect that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Soleno Therapeutics

Several hedge funds have recently bought and sold shares of the company. CenterBook Partners LP increased its holdings in shares of Soleno Therapeutics by 156.2% during the 3rd quarter. CenterBook Partners LP now owns 62,794 shares of the company’s stock worth $4,245,000 after acquiring an additional 38,282 shares during the last quarter. Kingdon Capital Management L.L.C. acquired a new stake in Soleno Therapeutics during the 3rd quarter valued at $20,348,000. Schroder Investment Management Group lifted its holdings in Soleno Therapeutics by 1,554.9% during the 3rd quarter. Schroder Investment Management Group now owns 280,296 shares of the company’s stock valued at $19,105,000 after purchasing an additional 263,359 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in Soleno Therapeutics by 25.7% during the third quarter. Avoro Capital Advisors LLC now owns 2,577,777 shares of the company’s stock worth $174,258,000 after purchasing an additional 527,777 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in Soleno Therapeutics by 255.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 280,984 shares of the company’s stock worth $18,995,000 after purchasing an additional 201,983 shares during the period. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Neutral Sentiment: Multiple law firms and claim services are issuing investor alerts reminding shareholders of the May 5, 2026 lead‑plaintiff deadline and encouraging affected investors to come forward. These notices increase visibility of the litigation but are procedural in nature. SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
• Negative Sentiment: Several firms (Hagens Berman, Kessler Topaz, Pomerantz, Rosen, etc.) have confirmed or publicized securities‑fraud class actions alleging material misstatements/omissions about Soleno’s Phase 3 program and the November 2025 disclosures about DCCR/VYKAT XR launch disruptions. This raises the risk of costly litigation, management distraction, and potential settlements. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: An analyst update from Oppenheimer (reported in media coverage) lowered expectations for the VYKAT XR launch and 2026 sales, trimming the growth/valuation story for Soleno and increasing downside risk if launch execution and uptake remain weak. A Look At Soleno Therapeutics (SLNO) Valuation As Oppenheimer Updates Vykat XR Launch And 2026 Sales Outlook

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.